Results 71 to 80 of about 492,192 (286)

Predicting gastrointestinal drug effects using contextualized metabolic models.

PLoS Computational Biology, 2019
Gastrointestinal side effects are among the most common classes of adverse reactions associated with orally absorbed drugs. These effects decrease patient compliance with the treatment and induce undesirable physiological effects.
Marouen Ben Guebila, Ines Thiele
doaj   +1 more source

Predicting new molecular targets for known drugs

Nature, 2009
Although drugs are intended to be selective, at least some bind to several physiological targets, explaining side effects and efficacy. Because many drug–target combinations exist, it would be useful to explore possible interactions computationally. Here
Michael J. Keiser, V. Setola, J. Irwin, Christian Laggner, Atheir I. Abbas, S. Hufeisen, Niels H. Jensen, M. B. Kuijer, Roberto C. Matos, T. Tran, R. Whaley, R. Glennon, J. Hert, Kelan L Thomas, D. D. Edwards, B. Shoichet, B. Roth   +16 more
semanticscholar   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source

Neurochemical and Physiological Effects of Cocaine Oscillate with Sequential Drug Treatment: Possibly a Major Factor in Drug Variability [PDF]

, 1995
Seymour M. Antelman, Anthony R. Caggiula, Susan Kiss, David J. Edwards, Donna Kocan, Richard L. Stiller   +5 more
openalex   +2 more sources

Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs

Molecular Oncology, EarlyView.
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza, David James, Emma Creagh, James T. Murray   +3 more
wiley   +1 more source

Advances in peptide-based drug delivery systems

Heliyon
Drug delivery systems (DDSs) are designed to deliver drugs to their specific targets to minimize their toxic effects and improve their susceptibility to clearance during targeted transport.
Sijie Guo, Jing Wang, Qi Wang, Jinxin Wang, Song Qin, Wenjun Li   +5 more
doaj   +1 more source

Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Drug-Induced Inotropic Effects in Early Drug Development. Part 2: Designing and Fabricating Microsystems for Assaying Cardiac Contractility With Physiological Relevance Using Human iPSC-Cardiomyocytes

Frontiers in Pharmacology, 2019
Contractility of the myocardium engines the pumping function of the heart and is enabled by the collective contractile activity of its muscle cells: cardiomyocytes.
Alexandre J. S. Ribeiro, Brian D. Guth, Brian D. Guth, Michael Engwall, Sandy Eldridge, C. Michael Foley, Liang Guo, Gary Gintant, John Koerner, Stanley T. Parish, Jennifer B. Pierson, Mathew Brock, Khuram W. Chaudhary, Yasunari Kanda, Brian Berridge   +14 more
doaj   +1 more source

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

Molecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh, Liping Su, Suet Lin Chia, Xiaohe Tian, Haslina Ahmad, Martin R. Gill   +5 more
wiley   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Long QT syndrome: Genetic implications and drug influence [PDF]

Vojnosanitetski Pregled, 2008
Savić Nataša, Gojković-Bukarica Ljiljana   +1 more
doaj   +1 more source